These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10369627)

  • 21. [Chlamydia pneumoniae and atherosclerosis].
    Andreasen JJ
    Ugeskr Laeger; 1997 Sep; 159(37):5503-7. PubMed ID: 9312918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Chlamydia pneumoniae and atherosclerosis--the hen, the egg or five feathers?].
    Møller K; Skinhøj P
    Ugeskr Laeger; 1999 Sep; 161(37):5173-4. PubMed ID: 10523951
    [No Abstract]   [Full Text] [Related]  

  • 23. Chlamydia pneumoniae, asthma, and COPD: what is the evidence?
    Hahn DL
    Ann Allergy Asthma Immunol; 1999 Oct; 83(4):271-88, 291; quiz 291-2. PubMed ID: 10541419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chlamydia pneumoniae in coronary artery disease.
    Gurfinkel E; Bozovich G; Mautner B; Anderson JL; Muhlestein JB; Carlquist J; Allen A; Trehan S; Nielson C; Hall S; Brady J; Egger M; Horne B; Lim T
    Circulation; 2000 Mar; 101(12):E118-9. PubMed ID: 10736300
    [No Abstract]   [Full Text] [Related]  

  • 25. Chlamydia pneumoniae and atherosclerotic risk in populations: the role of seroepidemiology.
    Siscovick DS; Schwartz SM; Caps M; Wang SP; Grayston JT
    J Infect Dis; 2000 Jun; 181 Suppl 3():S417-20. PubMed ID: 10839727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Role of Chlamydia pneumoniae in the pathogenesis of coronary disease].
    Kähler J; Köster R; Bräser JH; Schäfer P; Terres W; Hamm CW; Meinertz T
    Z Kardiol; 1999 Nov; 88(11):885-95. PubMed ID: 10643056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chlamydia pneumoniae and atherosclerosis.
    Wong YK; Gallagher PJ; Ward ME
    Heart; 1999 Mar; 81(3):232-8. PubMed ID: 10026342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of chronic Chlamydia infection with non-specific inflammation on cardiovascular complications in acute myocardial infarct].
    Jaber AJ; Murín J; Hricák V; Tomasovic B; Kinová S; Kozlíková K; Ghanem W; Radman A
    Vnitr Lek; 2003 Feb; 49(2):109-14. PubMed ID: 12728577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chlamydia pneumoniae, strain TWAR and atherosclerosis.
    Grayston JT; Kuo CC; Campbell LA; Benditt EP
    Eur Heart J; 1993 Dec; 14 Suppl K():66-71. PubMed ID: 8131792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease.
    Jackson LA; Stewart DK; Wang SP; Cooke DB; Cantrell T; Grayston JT
    J Antimicrob Chemother; 1999 Sep; 44(3):411-4. PubMed ID: 10511413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibiotic therapy in coronary heart disease--where do we currently stand?
    Anand V; Gupta S
    Cardiovasc Drugs Ther; 2001; 15(3):209-10. PubMed ID: 11713887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Infection hypothesis for the pathogenesis of atherosclerosis--caused by Chlamydia pneumoniae?].
    Durkalec J; Hasik J
    Przegl Lek; 1999; 56(4):299-301. PubMed ID: 10494168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials.
    Andraws R; Berger JS; Brown DL
    JAMA; 2005 Jun; 293(21):2641-7. PubMed ID: 15928286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Collaborative multidisciplinary workshop report: clinical antimicrobial trials for primary and secondary prevention of atherosclerotic cardiovascular disease.
    Rosen H; Muhlestein JB; Bartlett J; Chen S; Chikami G; Corson M; Shah PK; Gurfinkel E; Handsfield H; Jackson L; Knirsch C; Kronmal R; McCutchan JA; Shea S
    J Infect Dis; 2000 Jun; 181 Suppl 3():S582-4. PubMed ID: 10839764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chlamydia preumoniae in ischemic heart disease.
    Kaykov E; Abbou B; Friedstrom S; Hermoni D; Roguin N
    Isr Med Assoc J; 1999 Dec; 1(4):225-7. PubMed ID: 10731348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflammation, infection, or both in atherosclerosis: the ROXIS trial in perspective.
    Gurfinkel E
    J Infect Dis; 2000 Jun; 181 Suppl 3():S566-8. PubMed ID: 10839760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibiotics and heart disease. The story heats up.
    Harv Heart Lett; 1999 Jul; 9(11):4-6. PubMed ID: 10368527
    [No Abstract]   [Full Text] [Related]  

  • 38. Design of future intervention studies for Chlamydia pneumoniae in atherosclerosis.
    Grayston JT
    Am Heart J; 1999 Nov; 138(5 Pt 2):S556-7. PubMed ID: 10539875
    [No Abstract]   [Full Text] [Related]  

  • 39. The prevalence of Chlamydia pneumoniae antibodies in Thai patients with coronary artery disease.
    Leowattana W; Mahanonda N; Bhuripunyo K; Leelarasamee A; Pokum S; Suwimol B
    J Med Assoc Thai; 1999 Aug; 82(8):792-7. PubMed ID: 10511787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial.
    Dunne MW
    J Infect Dis; 2000 Jun; 181 Suppl 3():S572-8. PubMed ID: 10839762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.